How to treat the kidney complications with anti angiogenic therapy
What is the management of patients who develop kidney complications with anti angiogenic therapy?
It is important to monitor blood pressure and proteinuria in these patients. Angiotensin converting enzyme inhibitor (ACEi) or angiotensin receptor blocker is usually the first-line treatment of hypertension in these patients.
The non-dihydropyridine calcium channel blockers (verapamil, diltiazem) interact with the cytochrome P450 pathway and can increase tyrosine kinase inhibitor levels.
The drugs can continue unless the patient develops nephrotic syndrome, AKI, or TMA.
